Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial

Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial

(2017) G. Haidari et al.   Scientific Reports

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

(2016) Selidji T. Agnandji et al.   NEW ENGLAND JOURNAL OF MEDICINE

Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment

(2016) David K. Clarke et al.   VACCINE

Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review

(2016) Vincent Muturi-Kioi et al.   PLoS One

Clinical potential of electroporation for gene therapy and DNA vaccine delivery

(2015) Laure Lambricht et al.   Expert Opinion on Drug Delivery

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

(2015) Ana Maria Henao-Restrepo et al.   LANCET

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

(2015) Angela Huttner et al.   LANCET INFECTIOUS DISEASES

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults

(2015) Juliet Mpendo et al.   PLoS One

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)

(2015) Jonathan D. Fuchs et al.   Open Forum Infectious Diseases

Immune Activation with HIV Vaccines

(2014) A. S. Fauci et al.   SCIENCE

Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery

(2013) Spyros A. Kalams et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults

(2012) Spyros A. Kalams et al.   PLoS One

Plasmid DNA Gene Therapy by Electroporation: Principles and Recent Advances

(2011) Tatsufumi Murakami et al.   CURRENT GENE THERAPY

In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers

(2011) Sandhya Vasan et al.   PLoS One

Electroporation Gene Therapy Preclinical and Clinical Trials for Melanoma

(2010) Loree C. Heller et al.   CURRENT GENE THERAPY

IL-12 and IL-27 Sequential Gene Therapy via Intramuscular Electroporation Delivery for Eliminating Distal Aggressive Tumors

(2010) Shiguo Zhu et al.   JOURNAL OF IMMUNOLOGY

Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation

(2010) Karen E. Dolter et al.   VACCINE

Plasmid-Encoded Interleukin-15 Receptor α Enhances Specific Immune Responses Induced by a DNA Vaccine In Vivo

(2009) Kimberly A. Kraynyak et al.   HUMAN GENE THERAPY